Last reviewed · How we verify

ADT+second-generation antiandrogens ± chemotherapy

The First Affiliated Hospital with Nanjing Medical University · Phase 3 active Small molecule

ADT+second-generation antiandrogens ± chemotherapy is a Androgen deprivation therapy + androgen receptor antagonist ± chemotherapy Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently in Phase 3 development for Metastatic hormone-sensitive prostate cancer, Castration-resistant prostate cancer (with second-generation antiandrogens). Also known as: hormonal therapy or chemotherapy.

This combination suppresses androgen production and blocks androgen receptor signaling in prostate cancer cells, with optional chemotherapy to enhance cytotoxic effects.

This combination suppresses androgen production and blocks androgen receptor signaling in prostate cancer cells, with optional chemotherapy to enhance cytotoxic effects. Used for Metastatic hormone-sensitive prostate cancer, Castration-resistant prostate cancer (with second-generation antiandrogens).

At a glance

Generic nameADT+second-generation antiandrogens ± chemotherapy
Also known ashormonal therapy or chemotherapy
SponsorThe First Affiliated Hospital with Nanjing Medical University
Drug classAndrogen deprivation therapy + androgen receptor antagonist ± chemotherapy
TargetAndrogen receptor; testosterone/DHT synthesis (if abiraterone included)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Androgen deprivation therapy (ADT) reduces circulating testosterone, while second-generation antiandrogens (such as enzalutamide, abiraterone, or apalutamide) block androgen receptor function at the cellular level. The optional addition of chemotherapy (typically docetaxel) provides direct cytotoxic activity against rapidly dividing cancer cells. This multi-modal approach targets hormone-sensitive and castration-resistant prostate cancer through complementary mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ADT+second-generation antiandrogens ± chemotherapy

What is ADT+second-generation antiandrogens ± chemotherapy?

ADT+second-generation antiandrogens ± chemotherapy is a Androgen deprivation therapy + androgen receptor antagonist ± chemotherapy drug developed by The First Affiliated Hospital with Nanjing Medical University, indicated for Metastatic hormone-sensitive prostate cancer, Castration-resistant prostate cancer (with second-generation antiandrogens).

How does ADT+second-generation antiandrogens ± chemotherapy work?

This combination suppresses androgen production and blocks androgen receptor signaling in prostate cancer cells, with optional chemotherapy to enhance cytotoxic effects.

What is ADT+second-generation antiandrogens ± chemotherapy used for?

ADT+second-generation antiandrogens ± chemotherapy is indicated for Metastatic hormone-sensitive prostate cancer, Castration-resistant prostate cancer (with second-generation antiandrogens).

Who makes ADT+second-generation antiandrogens ± chemotherapy?

ADT+second-generation antiandrogens ± chemotherapy is developed by The First Affiliated Hospital with Nanjing Medical University (see full The First Affiliated Hospital with Nanjing Medical University pipeline at /company/the-first-affiliated-hospital-with-nanjing-medical-university).

Is ADT+second-generation antiandrogens ± chemotherapy also known as anything else?

ADT+second-generation antiandrogens ± chemotherapy is also known as hormonal therapy or chemotherapy.

What drug class is ADT+second-generation antiandrogens ± chemotherapy in?

ADT+second-generation antiandrogens ± chemotherapy belongs to the Androgen deprivation therapy + androgen receptor antagonist ± chemotherapy class. See all Androgen deprivation therapy + androgen receptor antagonist ± chemotherapy drugs at /class/androgen-deprivation-therapy-androgen-receptor-antagonist-chemotherapy.

What development phase is ADT+second-generation antiandrogens ± chemotherapy in?

ADT+second-generation antiandrogens ± chemotherapy is in Phase 3.

What are the side effects of ADT+second-generation antiandrogens ± chemotherapy?

Common side effects of ADT+second-generation antiandrogens ± chemotherapy include Hot flashes, Fatigue, Sexual dysfunction/erectile dysfunction, Gynecomastia, Nausea, Diarrhea (with second-generation antiandrogens).

What does ADT+second-generation antiandrogens ± chemotherapy target?

ADT+second-generation antiandrogens ± chemotherapy targets Androgen receptor; testosterone/DHT synthesis (if abiraterone included) and is a Androgen deprivation therapy + androgen receptor antagonist ± chemotherapy.

Related